KR20250044940A - 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도 - Google Patents

테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도 Download PDF

Info

Publication number
KR20250044940A
KR20250044940A KR1020257008973A KR20257008973A KR20250044940A KR 20250044940 A KR20250044940 A KR 20250044940A KR 1020257008973 A KR1020257008973 A KR 1020257008973A KR 20257008973 A KR20257008973 A KR 20257008973A KR 20250044940 A KR20250044940 A KR 20250044940A
Authority
KR
South Korea
Prior art keywords
compound
och
mmol
methyl
paragraph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257008973A
Other languages
English (en)
Korean (ko)
Inventor
시몬 촬스 구데이커
샤라다 래버디
준 량
다니엘 프레드 오트와인
니콜라스 촬스 레이
샤오징 왕
제이슨 즈비그
비롱 장
토미 라이
지앙펑 리아오
지구오 리우
존 와이
타오 왕
준 리
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20250044940A publication Critical patent/KR20250044940A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020257008973A 2014-12-18 2015-12-17 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도 Pending KR20250044940A (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201462093929P 2014-12-18 2014-12-18
US62/093,929 2014-12-18
US201562110998P 2015-02-02 2015-02-02
US62/110,998 2015-02-02
US201562142077P 2015-04-02 2015-04-02
US62/142,077 2015-04-02
KR1020237024959A KR102785474B1 (ko) 2014-12-18 2015-12-17 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도
PCT/EP2015/080119 WO2016097072A1 (en) 2014-12-18 2015-12-17 TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020237024959A Division KR102785474B1 (ko) 2014-12-18 2015-12-17 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도

Publications (1)

Publication Number Publication Date
KR20250044940A true KR20250044940A (ko) 2025-04-01

Family

ID=54850193

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020257008973A Pending KR20250044940A (ko) 2014-12-18 2015-12-17 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도
KR1020177016260A Active KR102559719B1 (ko) 2014-12-18 2015-12-17 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도
KR1020257008970A Pending KR20250044939A (ko) 2014-12-18 2015-12-17 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도
KR1020237024959A Active KR102785474B1 (ko) 2014-12-18 2015-12-17 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020177016260A Active KR102559719B1 (ko) 2014-12-18 2015-12-17 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도
KR1020257008970A Pending KR20250044939A (ko) 2014-12-18 2015-12-17 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도
KR1020237024959A Active KR102785474B1 (ko) 2014-12-18 2015-12-17 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도

Country Status (33)

Country Link
US (4) US9980947B2 (https=)
EP (2) EP3760623B1 (https=)
JP (5) JP6679147B2 (https=)
KR (4) KR20250044940A (https=)
CN (6) CN112375077A (https=)
AU (3) AU2015367509B2 (https=)
BR (1) BR112017007662B1 (https=)
CA (1) CA2963736A1 (https=)
CL (2) CL2017000814A1 (https=)
CO (1) CO2017003070A2 (https=)
CR (1) CR20170250A (https=)
DK (1) DK3233852T3 (https=)
EA (1) EA032311B1 (https=)
ES (1) ES2819448T3 (https=)
HR (1) HRP20201396T1 (https=)
HU (1) HUE050466T2 (https=)
IL (5) IL301960B2 (https=)
LT (1) LT3233852T (https=)
MA (1) MA53837A (https=)
MX (3) MX395013B (https=)
MY (1) MY198354A (https=)
NZ (1) NZ769496A (https=)
PE (1) PE20171330A1 (https=)
PH (1) PH12017501140A1 (https=)
PL (1) PL3233852T3 (https=)
PT (1) PT3233852T (https=)
RS (1) RS60824B1 (https=)
SG (3) SG10201913913VA (https=)
SI (1) SI3233852T1 (https=)
TW (5) TWI874834B (https=)
UA (1) UA122868C2 (https=)
WO (1) WO2016097072A1 (https=)
ZA (1) ZA202108745B (https=)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX388871B (es) 2014-06-27 2025-03-20 Nogra Pharma Ltd Moduladores del receptor arilo y metodos para elaborar y usar los mismos.
TWI874834B (zh) 2014-12-18 2025-03-01 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
WO2016097071A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Estrogen receptor modulators and uses thereof
KR20240142622A (ko) * 2015-10-01 2024-09-30 올레마 파마슈티컬스 인코포레이티드 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
JP2019001715A (ja) * 2015-10-30 2019-01-10 協和発酵キリン株式会社 三環性化合物
LT3386500T (lt) 2015-12-09 2022-12-27 The Board Of Trustees Of The University Of Illinois Selektyvūs estrogenų receptorių slopintojai benzotiofeno pagrindu
KR102479822B1 (ko) * 2016-02-05 2022-12-21 인벤티스바이오 엘엘씨 선택적 에스트로겐 수용체 분해제 및 이들의 용도
EA034994B1 (ru) 2016-02-15 2020-04-15 Санофи 6,7-дигидро-5h-бензо[7]аннуленовые производные в качестве модуляторов эстрогеновых рецепторов
WO2017182493A1 (en) 2016-04-20 2017-10-26 Astrazeneca Ab Indazole derivatives for use in down-regulation of the estrogen receptor for the treatment of cancer
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
CN109843882A (zh) * 2016-06-16 2019-06-04 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
EP3472162B1 (en) * 2016-06-16 2021-11-17 F. Hoffmann-La Roche AG Heteroaryl estrogen receptor modulators and uses thereof
CN107543871A (zh) * 2016-06-29 2018-01-05 重庆华邦胜凯制药有限公司 分离测定帕布昔利布中间体z1及其有关物质的方法
RU2019102647A (ru) 2016-07-01 2020-08-03 Г1 Терапьютикс, Инк. Антипролиферационные средства на основе пиримидина
US10149839B2 (en) 2016-07-25 2018-12-11 Astrazeneca Ab Chemical compounds
IL265537B2 (en) * 2016-09-27 2023-04-01 Radius Health Inc Methods of treating ovarian cancer
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
EP3640251B1 (en) * 2016-10-24 2021-12-08 Astrazeneca AB 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
CN110139863B (zh) * 2016-10-28 2022-02-18 罗欣健康科技发展(北京)有限公司 作为雌激素受体降解剂的吲哚并取代哌啶类化合物
ES3039455T3 (en) * 2016-11-17 2025-10-21 Sanofi Sa Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
WO2018108954A1 (en) 2016-12-12 2018-06-21 F. Hoffmann-La Roche Ag Process for the preparation of 2-(3-(fluoromethyl)azetidin-1-yl)ethan-1-ol
EA037533B9 (ru) * 2016-12-16 2021-05-27 Астразенека Аб 6,7,8,9-ТЕТРАГИДРО-3H-ПИРАЗОЛО[4,3-f]ИЗОХИНОЛИНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ РАКА
MX2019008158A (es) 2017-01-06 2019-12-09 G1 Therapeutics Inc Terapia de combinacion para el tratamiento del cancer.
WO2018130123A1 (zh) * 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的五环类化合物及其应用
WO2018138739A1 (en) 2017-01-27 2018-08-02 Sun Pharma Advanced Research Company Limited Novel antiestrogenic heterocyclic compounds
PL3494116T3 (pl) 2017-01-30 2020-04-30 Astrazeneca Ab Modulatory receptora estrogenowego
KR20190117582A (ko) 2017-02-10 2019-10-16 쥐원 쎄라퓨틱스, 인크. 벤조티오펜 에스트로겐 수용체 조정제
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
WO2019006393A1 (en) 2017-06-29 2019-01-03 G1 Therapeutics, Inc. Morphic forms of git38 and methods of manufacture thereof
EP3434272A1 (en) 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
NZ764463A (en) * 2017-11-14 2023-07-28 Kind Pharmaceutical Heterocyclic compound and application thereof in medicine
EA038160B1 (ru) * 2017-11-30 2021-07-15 Астразенека Аб Модуляторы рецептора эстрогена
US10519152B2 (en) 2017-12-21 2019-12-31 Astrazeneca Ab Compounds and their use in treating cancer
SG11202006942WA (en) 2018-01-22 2020-08-28 Radius Pharmaceuticals Inc Estrogen receptor-modulating compounds
CN111770924B (zh) * 2018-04-04 2023-05-09 深圳福沃药业有限公司 用于治疗乳腺癌的雌激素受体降解剂
CA3099155A1 (en) 2018-05-14 2019-11-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CR20200621A (es) * 2018-06-21 2021-02-03 Hoffmann La Roche Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3 fluoropropil)azetidin-3-il)amino)fenil)-3-(metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
JP7571006B2 (ja) * 2018-08-17 2024-10-22 ジェネンテック， インコーポレイテッド 乳がんの処置のための診断的および治療的方法
BR112021003440A2 (pt) 2018-09-07 2021-05-18 Sanofi sais de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil) pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxilato de metila e seu processo de preparação
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN120698983A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
CA3128521A1 (en) * 2019-02-27 2020-09-03 Millennium Pharmaceuticals, Inc. Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
CA3138197A1 (en) 2019-05-14 2020-11-19 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2020254289A1 (en) * 2019-06-17 2020-12-24 Ucb Pharma Gmbh N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis
KR20220034129A (ko) * 2019-07-07 2022-03-17 올레마 파마슈티컬스 인코포레이티드 에스트로겐 수용체 길항제 요법
US12428424B2 (en) 2019-07-22 2025-09-30 Radius Pharmaceuticals, Inc. Estrogen receptor-modulating compounds
KR20220044528A (ko) 2019-08-06 2022-04-08 리커리엄 아이피 홀딩스, 엘엘씨 돌연변이체를 치료하기 위한 에스트로겐 수용체 조절제
TW202126299A (zh) * 2019-09-19 2021-07-16 美商托特斯藥品公司 治療性共軛物
EP4037768B1 (en) 2019-10-01 2023-10-11 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
EP4058464A1 (en) 2019-11-13 2022-09-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
AU2020399168A1 (en) 2019-12-09 2022-07-28 Sanofi Crystalline form of a 7H-benzo[7]annulene-2-carboxylic acid derivative
KR20220119415A (ko) 2019-12-20 2022-08-29 씨4 테라퓨틱스, 인코포레이티드 Egfr 분해를 위한 이소인돌리논 및 인다졸 화합물
KR20220119658A (ko) * 2019-12-20 2022-08-30 리커리엄 아이피 홀딩스, 엘엘씨 조합물
WO2021143822A1 (zh) * 2020-01-16 2021-07-22 江苏恒瑞医药股份有限公司 并环酰亚胺类衍生物、其制备方法及其在医药上的应用
WO2021143816A1 (zh) * 2020-01-16 2021-07-22 江苏恒瑞医药股份有限公司 稠合酰亚胺类衍生物、其制备方法及其在医药上的应用
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
TW202146412A (zh) 2020-03-05 2021-12-16 美商Ｃ４醫藥公司 用於標靶降解brd9之化合物
CA3169679A1 (en) * 2020-03-06 2021-09-10 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases
CN115667275B (zh) * 2020-04-21 2024-02-23 南京再明医药有限公司 含硼化合物及其应用
MX2022013391A (es) 2020-04-24 2022-11-30 Astrazeneca Ab Pauta posologica para el tratamiento del cancer.
MX2022013258A (es) 2020-04-24 2022-11-14 Astrazeneca Ab Formulaciones farmaceuticas.
CN115551513B (zh) * 2020-05-12 2025-05-02 基因泰克公司 使用包含gdc-9545和cdk4/6抑制剂的组合疗法治疗乳腺癌
AU2021269612A1 (en) 2020-05-15 2023-01-05 Jiangsu Simcere Pharmaceutical Co., Ltd. Pyrrolidine compound and use thereof
TW202214626A (zh) * 2020-06-12 2022-04-16 大陸商江蘇先聲藥業有限公司 雌激素受體調節劑化合物及其用途
WO2022005943A2 (en) 2020-06-30 2022-01-06 Genentech, Inc. Processes for making serd tricyclic compounds having a substituted phenyl or pyridinyl moiety
IL300397A (en) 2020-08-05 2023-04-01 C4 Therapeutics Inc Compounds for targeted knockdown of RET
CN114105977B (zh) * 2020-08-28 2023-09-01 先声再明医药有限公司 雌激素受体调节剂化合物及其用途
TW202233572A (zh) 2020-10-19 2022-09-01 法商賽諾菲公司 新穎之經取代的6,7-二氫-5h-苯並[7]輪烯衍生物，其製備方法及其治療用途
WO2022084280A1 (en) 2020-10-19 2022-04-28 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
EP4267578A4 (en) 2020-12-23 2024-11-20 Recurium IP Holdings, LLC ESTROGEN RECEPTOR MODULATORS
WO2022166983A1 (zh) * 2021-02-08 2022-08-11 贝达药业股份有限公司 杂芳基并哌啶类衍生物及其药物组合物和应用
TWI808648B (zh) 2021-02-16 2023-07-11 美商建南德克公司 使用包含gdc-9545及gdc-0077之組合療法治療乳癌
JP2024516024A (ja) 2021-05-03 2024-04-11 ニューベイション・バイオ・インコーポレイテッド 抗がん核内ホルモン受容体標的化化合物
MX2023014059A (es) 2021-06-08 2024-03-12 C4 Therapeutics Inc Terapeuticos para la degradacion de una proteina quiinasa de serina/ treonina mutante.
TW202317539A (zh) * 2021-07-15 2023-05-01 大陸商四川海思科製藥有限公司 芳氨基衍生物雌激素受體調節劑及其用途
KR102689151B1 (ko) * 2021-09-06 2024-07-29 연세대학교 산학협력단 Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물
CN118317948A (zh) * 2021-10-08 2024-07-09 阿佐拉治疗股份有限公司 芳烃受体激动剂的衍生物
TW202333704A (zh) * 2021-11-12 2023-09-01 大陸商先聲藥業有限公司 用於治療腫瘤的藥物組合及其應用
WO2023091550A1 (en) * 2021-11-18 2023-05-25 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases
JP7805677B2 (ja) * 2021-12-28 2026-01-26 浙江揚歴医薬技術有限公司 テトラヒドロシクロヘプタインダゾール化合物の結晶
CN116804008A (zh) * 2022-03-24 2023-09-26 烟台创和生物科技有限公司 雌激素受体降解剂及其制备方法和应用
AU2023262166A1 (en) 2022-04-28 2024-10-17 F. Hoffmann-La Roche Ag Solid form of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9- tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol tartrate
WO2023221123A1 (en) * 2022-05-20 2023-11-23 Olema Pharmaceuticals, Inc. Crystalline forms of an estrogen receptor antagonist
WO2023221122A1 (en) * 2022-05-20 2023-11-23 Olema Pharmaceuticals, Inc. Salts and solid forms of an estrogen receptor antagonist
WO2024015506A1 (en) * 2022-07-14 2024-01-18 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-mediated disorders
WO2024017131A1 (zh) * 2022-07-21 2024-01-25 贝达药业股份有限公司 杂芳基并哌啶类衍生物及其药物组合物和应用
CN115109058B (zh) * 2022-07-27 2023-04-07 黑龙江中医药大学 一种用于治疗胃癌的药物及其制备方法
WO2024030968A1 (en) 2022-08-03 2024-02-08 Brystol-Myers Squibb Company Compounds for modulating ret protein
CA3261772A1 (en) * 2022-08-19 2024-02-22 Olema Pharmaceuticals, Inc. Estrogen Receptor Modulators and Their Uses
AU2023324856A1 (en) * 2022-08-19 2025-01-30 Olema Pharmaceuticals, Inc. 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole derivatives as estrogen receptor modulators for the treatment of cancer
EP4577542A1 (en) * 2022-08-25 2025-07-02 Sanofi Novel substituted 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole carboxylic acid derivatives, processes for their preparation and therapeutic uses thereof
IL320302A (en) 2022-10-17 2025-06-01 Astrazeneca Ab SERD combinations for cancer treatment
CN120112288A (zh) * 2022-10-28 2025-06-06 南京再明医药有限公司 用于治疗肿瘤的药物组合、药物组合物及其用途
WO2024097980A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Ret-ldd protein inhibitors
EP4611901A1 (en) 2022-11-04 2025-09-10 Bristol-Myers Squibb Company Ret-ldd protein degraders
WO2024100236A1 (en) 2022-11-11 2024-05-16 Astrazeneca Ab Combination therapies for the treatment of cancer
US20240180893A1 (en) 2022-11-17 2024-06-06 Astrazeneca Ab Methods of treatment of breast cancer
CN115894485B (zh) * 2023-03-03 2023-06-27 山东绿叶制药有限公司 杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用
US11773092B1 (en) 2023-03-27 2023-10-03 King Faisal University Pyrido[3,4-b]indol-1-one compounds as antibacterial agents
TW202508573A (zh) 2023-05-11 2025-03-01 瑞典商阿斯特捷利康公司 用於治療癌症之組合療法
EP4735452A2 (en) 2023-06-30 2026-05-06 Merck Patent GmbH Heterobifunctional compounds for the degradation of kras protein
WO2025103409A1 (zh) * 2023-11-16 2025-05-22 南京同诺康医药科技有限公司 Nmt抑制剂及其制备方法和用途
TW202543650A (zh) 2024-03-08 2025-11-16 美商海爾達醫療運營公司 異雙官能化合物及其在治療疾病中之用途
CN118791392B (zh) * 2024-06-18 2026-02-17 华中科技大学 一种合成依拉司群的方法及中间体化合物
US20260008798A1 (en) 2024-07-02 2026-01-08 Hoffmann-La Roche Inc. Palladium catalyzed synthesis of aminoaldehyde intermediates

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE398789C (de) 1923-03-03 1924-07-15 L V Kramolin Verfahren und Einrichtung zur Verhinderung des Mithoerens beim Telephon- und Telegraphenverkehr mittels elektrischer Wellen und zum Vielfachverkehr mittels elektromagnetischer Wellen
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
SE455604B (sv) 1982-06-29 1988-07-25 Stiftelsen Ind Organisk Elektr Sett att framstella fenetylaminer medelst elektrokemisk reduktion
US5206377A (en) 1991-12-05 1993-04-27 Whitby Research, Inc. Compounds useful as antiproliferative agents
EP0620222A3 (en) 1993-04-14 1995-04-12 Lilly Co Eli Tetrahydro-beta-carbolines.
IL115582A0 (en) * 1994-10-14 1996-01-19 Lilly Co Eli Methods for treating resistant tumors
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
US6987115B2 (en) 2000-12-08 2006-01-17 Smithkline Beecham Corporation Antibacterial compounds
ES2248412T3 (es) 2001-02-12 2006-03-16 Lilly Icos Llc Derivados de carbolina.
US6951961B2 (en) 2002-05-17 2005-10-04 Marina Nikolaevna Protopopova Methods of use and compositions for the diagnosis and treatment of infectious disease
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
ATE482747T1 (de) 2003-04-11 2010-10-15 High Point Pharmaceuticals Llc Neue amide derivate und deren pharmazeutische verwendungen
WO2005034857A2 (en) 2003-09-05 2005-04-21 Sequella, Inc. Methods and compositions comprising diamines as new anti-tubercular therapeutics
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
UA92317C2 (ru) * 2004-03-15 2010-10-25 Пи-Ти-Си ТЕРАПЬЮТИКС, ИНК. Производные карболина, пригодные для ингибирования развития кровеносных сосудов
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US20080103164A1 (en) 2004-08-02 2008-05-01 Kristjan Gudmundsson Useful compounds for hpv infection
WO2007002051A1 (en) 2005-06-22 2007-01-04 Smithkline Beecham Corporation Carboline derivatives and their use as inhibitors of flaviviridae infections
SI1934174T1 (sl) 2005-10-07 2011-08-31 Exelixis Inc Inhibitorji MEK in postopki za njihovo uporabo
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
US20100158858A1 (en) 2007-04-13 2010-06-24 Liangxian Cao Administration of carboline derivatives useful in the treatment of cancer and other diseases
CN102015711B (zh) 2008-04-29 2013-05-01 诺瓦提斯公司 用于治疗寄生虫病的螺-吲哚衍生物
US9292307B2 (en) 2008-07-30 2016-03-22 Kyocera Corporation User interface generation apparatus
EP2323651A2 (en) 2008-08-05 2011-05-25 Summit Corporation Plc Compounds for the treatment of flaviviral infections
WO2010015816A2 (en) 2008-08-06 2010-02-11 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
WO2010029313A1 (en) 2008-09-11 2010-03-18 Summit Corporation Plc. Antiinfective compounds
WO2010049678A2 (en) 2008-10-31 2010-05-06 Summit Corporation Plc Treatment of energy utilization diseases
US20120040916A1 (en) 2008-12-22 2012-02-16 Massachusetts Institute Of Technology Molecular inhibitors of the wnt/beta-catenin pathway
US20120046242A1 (en) 2008-12-24 2012-02-23 Massachusetts Institute Of Technology Molecular activators of the wnt/beta-catenin pathway
WO2010107485A1 (en) 2009-03-17 2010-09-23 The Trustees Of Columbia University In The City Of New York E3 ligase inhibitors
WO2010114900A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted indolo-piperidine compounds
WO2010138685A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating prostate conditions
US20120202801A1 (en) * 2009-05-27 2012-08-09 Liangxian Cao Methods for treating breast cancer
MX373926B (es) * 2009-05-27 2020-07-10 Ptc Therapeutics Inc Metodos para tratar cancer y estados no neoplasicos.
WO2010138659A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating brain tumors
WO2010138695A1 (en) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
WO2010138652A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating kaposi sarcoma
WO2011150162A1 (en) 2010-05-27 2011-12-01 Ptc Therapeutics, Inc. Methods for treating viral conditions
RS56042B1 (sr) 2010-06-10 2017-09-29 Seragon Pharmaceuticals Inc Modulatori estrogenih receptora i njihove upotrebe
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
TW201500358A (zh) * 2010-12-16 2015-01-01 赫夫門羅氏藥廠股份有限公司 三環ｐｉ３ｋ抑制劑化合物及其使用方法
CA2819299A1 (en) 2010-12-24 2012-06-28 Merck Sharp & Dohme B.V. N-substituted azetidine derivatives
WO2013090829A1 (en) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
CN104508126B (zh) 2012-03-23 2017-06-30 科德克希思公司 用于合成色胺和色胺类似物的衍生物的生物催化剂和方法
EP2828256B1 (en) 2012-03-23 2019-07-03 Novartis AG Chemical process for preparing spiroindolones and intermediates thereof
DE102012209622A1 (de) 2012-06-08 2013-12-12 Robert Bosch Gmbh Zahnradmaschine mit hydrodynamisch und hydrostatisch gelagertem Lagerzapfen
EP2682119A1 (en) 2012-07-03 2014-01-08 Université Libre de Bruxelles Aromatic N-heterocycle derivatives for use as medicine
BR112015002493A8 (pt) * 2012-08-30 2019-07-30 Hoffmann La Roche composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, kit e uso de um composto”
EP2738173A1 (en) 2012-11-28 2014-06-04 Commissariat A L'energie Atomique Et Aux Energies Alternatives Heterocyclic compounds as inhibitors of the sodium iodide symporter
UY35590A (es) 2013-05-28 2014-11-28 Astrazeneca Ab Nuevos compuestos para el tratamiento del cáncer
CA2915534A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
EA031077B1 (ru) 2013-06-19 2018-11-30 Серагон Фармасьютикалз, Инк. Модулятор рецептора эстрогена и его применения
PL3062791T3 (pl) 2013-10-28 2020-06-15 Drexel University Nowoczesne terapie zaburzeń uwagi i zaburzeń poznawczych oraz otępienia związanych z zaburzeniem neurodegeneracyjnym
EP3089747A1 (en) 2013-12-06 2016-11-09 F. Hoffmann-La Roche AG Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
WO2015136016A2 (en) 2014-03-13 2015-09-17 F. Hoffmann-La Roche Ag Therapeutic combinations with estrogen receptor modulators
SG11201607339VA (en) 2014-03-13 2016-10-28 Hoffmann La Roche Methods and compositions for modulating estrogen receptor mutants
MX388871B (es) 2014-06-27 2025-03-20 Nogra Pharma Ltd Moduladores del receptor arilo y metodos para elaborar y usar los mismos.
TWI874834B (zh) 2014-12-18 2025-03-01 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
US20160175284A1 (en) 2014-12-18 2016-06-23 Genentech, Inc. Estrogen receptor modulators and uses thereof
WO2016097071A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Estrogen receptor modulators and uses thereof
KR20240142622A (ko) 2015-10-01 2024-09-30 올레마 파마슈티컬스 인코포레이티드 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
KR102479822B1 (ko) 2016-02-05 2022-12-21 인벤티스바이오 엘엘씨 선택적 에스트로겐 수용체 분해제 및 이들의 용도

Also Published As

Publication number Publication date
HUE050466T2 (hu) 2020-12-28
SG10202100799PA (en) 2021-03-30
IL301960A (en) 2023-06-01
TWI875674B (zh) 2025-03-01
EP3760623A1 (en) 2021-01-06
TWI874834B (zh) 2025-03-01
US12233052B2 (en) 2025-02-25
AU2020200407A1 (en) 2020-02-13
EA201791239A8 (ru) 2019-01-31
IL251370B (en) 2020-02-27
MA53837A (fr) 2021-11-10
CN112375078A (zh) 2021-02-19
IL301960B1 (en) 2024-04-01
MX2022007975A (es) 2022-07-05
SI3233852T1 (sl) 2020-10-30
US9980947B2 (en) 2018-05-29
MX395013B (es) 2025-03-24
MX376763B (es) 2025-03-07
TWI784255B (zh) 2022-11-21
AU2020200407B2 (en) 2021-04-08
IL270653B (en) 2021-12-01
TWI699363B (zh) 2020-07-21
CL2019000431A1 (es) 2019-07-12
TW201636348A (zh) 2016-10-16
SG11201704401TA (en) 2017-07-28
ES2819448T3 (es) 2021-04-16
TW202534076A (zh) 2025-09-01
CO2017003070A2 (es) 2017-07-11
EP3233852A1 (en) 2017-10-25
EA032311B1 (ru) 2019-05-31
JP6679147B2 (ja) 2020-04-15
WO2016097072A1 (en) 2016-06-23
RS60824B1 (sr) 2020-10-30
EP3760623C0 (en) 2026-03-18
TW202028204A (zh) 2020-08-01
LT3233852T (lt) 2020-10-12
JP2024028785A (ja) 2024-03-05
CL2017000814A1 (es) 2017-12-29
TW202323253A (zh) 2023-06-16
IL287326A (en) 2021-12-01
MX2020003532A (es) 2020-07-29
HRP20201396T1 (hr) 2020-11-27
IL251370A0 (en) 2017-05-29
PH12017501140A1 (en) 2018-03-05
DK3233852T3 (da) 2020-09-14
JP2026067858A (ja) 2026-04-21
BR112017007662B1 (pt) 2021-11-03
AU2015367509B2 (en) 2020-01-02
BR112017007662A2 (pt) 2017-12-19
CN107108611B (zh) 2020-09-25
TW202506643A (zh) 2025-02-16
CN117865872A (zh) 2024-04-12
CN107108611A (zh) 2017-08-29
US20180235945A1 (en) 2018-08-23
US20160175289A1 (en) 2016-06-23
EA201791239A1 (ru) 2017-10-31
CN112457310A (zh) 2021-03-09
IL287326B1 (en) 2023-05-01
US10966963B2 (en) 2021-04-06
JP7446348B2 (ja) 2024-03-08
JP7792942B2 (ja) 2025-12-26
IL287326B2 (en) 2023-09-01
NZ730448A (en) 2021-02-26
CA2963736A1 (en) 2016-06-23
KR20250044939A (ko) 2025-04-01
JP2020073493A (ja) 2020-05-14
KR20230113416A (ko) 2023-07-28
SG10201913913VA (en) 2020-03-30
AU2021200352B2 (en) 2022-12-15
US20210236473A1 (en) 2021-08-05
BR112017007662A8 (pt) 2021-10-05
EP3233852B1 (en) 2020-07-15
MY198354A (en) 2023-08-28
US20250114338A1 (en) 2025-04-10
KR20170097651A (ko) 2017-08-28
ZA202108745B (en) 2024-10-30
IL311006A (en) 2024-04-01
PT3233852T (pt) 2020-09-10
HK1243074A1 (zh) 2018-07-06
EP3760623B1 (en) 2026-03-18
KR102785474B1 (ko) 2025-03-26
PE20171330A1 (es) 2017-09-13
PL3233852T3 (pl) 2020-12-14
UA122868C2 (uk) 2021-01-13
CN112375078B (zh) 2023-12-19
CN112375077A (zh) 2021-02-19
AU2021200352A1 (en) 2021-03-18
MX2017007489A (es) 2017-10-18
CR20170250A (es) 2017-07-19
JP7128169B2 (ja) 2022-08-30
JP2022088416A (ja) 2022-06-14
KR102559719B1 (ko) 2023-07-26
IL301960B2 (en) 2024-08-01
AU2015367509A1 (en) 2017-04-13
CN118005631A (zh) 2024-05-10
US20230045776A9 (en) 2023-02-09
NZ769496A (en) 2023-09-29
JP2017538725A (ja) 2017-12-28

Similar Documents

Publication Publication Date Title
JP7792942B2 (ja) テトラヒドロ－ピリド［３，４－ｂ］インドールエストロゲン受容体モジュレーター及びその使用
HK40107389A (zh) 四氢-吡啶并[3，4-b]吲哚雌激素受体调节剂及其用途
HK40041467A (en) Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
HK40041466A (en) Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
NZ730448B2 (en) TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250318

Application number text: 1020237024959

Filing date: 20230720

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250417

Comment text: Request for Examination of Application